Aerovate Therapeutics, INC Form 4 insider transactions

Aerovate Therapeutics is set to acquire Jade Biosciences, a company focused on developing therapies for autoimmune diseases, through a merger agreement.

Aerovate Therapeutics and Jade Biosciences have entered into a merger agreement, with Aerovate acquiring Jade, pending stockholder approval and other customary conditions.

Aerovate Therapeutics is set to acquire Jade Biosciences through a merger, aiming to expand its pipeline with Jade's autoimmune disease therapies.

Aerovate Therapeutics and Jade Biosciences have announced a definitive merger agreement, subject to stockholder approval and other customary conditions, aimed at creating a combined company focused on advancing innovative therapies.

Aerovate Therapeutics and Jade Biosciences announced a merger agreement, with Jade receiving a $300 million private investment to advance its autoimmune disease pipeline.

Aerovate Therapeutics and Jade Biosciences have announced a merger agreement to create a company focused on advancing Jade Biosciences' portfolio of novel therapies for autoimmune diseases.

Benjamin T. Dake, an officer at Aerovate Therapeutics, exercised stock options to acquire common stock at a price of $1.74 per share.

RA Capital Management and related entities increased their holdings in Aerovate Therapeutics, acquiring 928,110 shares at an average price of $1.67.

George A. Eldridge, CFO of Aerovate Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Marinus Verwijs, Chief Technical Officer of Aerovate Therapeutics, sold 10,600 shares of common stock on June 14, 2024, under a pre-arranged 10b5-1 trading plan.

Hunter Gillies, Chief Medical Officer of Aerovate Therapeutics, executed transactions involving stock options and common stock under a pre-arranged Rule 10b5-1 trading plan.

RA Capital Management and related entities report acquiring stock options in Aerovate Therapeutics, Inc.

Donald J. Santel, a director of Aerovate Therapeutics, acquired stock options for 12,500 shares on June 5, 2024.

Director Joshua Resnick acquired 12,500 stock options in Aerovate Therapeutics, Inc. on June 5, 2024.

Director Maha Katabi acquired stock options for 12,500 shares of Aerovate Therapeutics, Inc. on June 5, 2024.

Mark T. Iwicki, a director of Aerovate Therapeutics, acquired stock options for 12,500 shares on June 5, 2024.

Director David S. Grayzel reports the acquisition of stock options in Aerovate Therapeutics, with vesting conditions tied to continued service and the next annual meeting.

Director Habib J Dable acquired 12,500 stock options in Aerovate Therapeutics on June 5, 2024.

Director Allison Dorval acquired stock options for 12,500 shares of Aerovate Therapeutics on June 5, 2024.

Chief Medical Officer Hunter Gillies exercised stock options and sold a portion of the acquired shares of Aerovate Therapeutics, Inc. on May 17, 2024, under a pre-arranged trading plan.

Timothy Noyes, CEO of Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Marinus Verwijs, Chief Technical Officer of Aerovate Therapeutics, sold 1,981 shares of common stock at an average price of $21.015 under a pre-arranged trading plan.

Aerovate Therapeutics' CEO, Timothy Noyes, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Benjamin T. Dake, an officer at Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Hunter Gillies, Chief Medical Officer of Aerovate Therapeutics, reports the sale of common stock and exercise of stock options under a pre-arranged trading plan.

Aerovate Therapeutics CEO Timothy P. Noyes exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

George Eldridge, CFO of Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director David S. Grayzel reported the sale of 11,882 shares of Aerovate Therapeutics, Inc. common stock at an average price of $28.15 on April 9, 2024.

CEO Timothy Noyes exercised stock options and sold shares of Aerovate Therapeutics under a pre-arranged Rule 10b5-1 trading plan.

Benjamin T. Dake, an officer at Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.